
DOI: 10.4103/ijmr.IJMR 800 19

## Clinical Image



## <sup>18</sup>F FDG PET/CT clearly showed a case of lymphoma involving kidneys & bones without morphological abnormality



**Fig. 1.** Renal ultrasound before treatment indicated that there were no obvious abnormalities in the size, shape and sonographic manifestations of both kidneys. **Panel A** and **B** show the left kidney and **C** and **D** represent the right kidney.


**Fig. 2.** PET/CT images before chemotherapy. **Panel A-C** show renal PET, CT and PET/CT fusion images, respectively. **Panel D-F** show PET, CT and fused PET/CT images of the left femoral neck, respectively. **(G)** MIP image shows abnormal FDG uptake in the bilateral kidneys and humerus, left femoral neck and retroperitoneal lymph nodes. The SUV $_{\rm max}$  of kidney and bone lesions were 18.1 and 17.0, respectively. Arrows indicate lesions. FDG PET/CT, flurodeoxyglucose positron-emission computed tomography, MIP, maximum intensity projection; SUV $_{\rm max}$ , maximum standardized uptake value.

A 31 yr old male† presented to the Infectious Diseases Department of Yichang Central People's Hospital, Hubei province, P.R. China, in June 2017, with a fever of unknown origin for over three weeks. The positive laboratory results mainly included erythrocytopenia (3.62×10¹²/l; normal range: 4.3-5.8), leukopenia (3.21×10⁰/l; normal range: 3.5-9.5), thrombocytopenia (118×10⁰/l; normal range: 125-350) and a marked increase in the level of lactate dehydrogenase (1208 IU/l; normal range: 120-250).

However, imaging examinations, including non-enhanced chest and abdominal computed

tomography (CT) and abdominal ultrasound were unremarkable (Fig. 1). A whole-body <sup>18</sup>Fluorine labelled fluorodeoxyglucose positron-emission computed tomography/CT (<sup>18</sup>F-FDG PET/CT) was done to look for occult infection or malignancy. PET/CT images (Fig. 2) showed abnormally elevated FDG uptake in bilateral kidneys and humerus, left femoral neck and retroperitoneal lymph nodes (all <1 cm in diameter) with a maximum standardized uptake value (SUV<sub>max</sub>) of 18.1. No obvious morphological abnormalities were observed in these hypermetabolic lesions on non-enhanced

<sup>&</sup>lt;sup>†</sup>Consent to publish clinical information and images obtained from the patient.



**Fig. 3.** The left femur neck lesion biopsy under the guidance of PET/CT. (**A**) Haematoxylin and eosin staining showing normal bone marrow structural destruction, with small remnants of adipose tissue and proliferating fibrous connective tissue and atypical lymphocyte infiltration. Immunohistochemical results: (**B**) MPO (-), CD235 (erythrocyte+), CD61 (-), CD3 (+), (**C**) CD20 (-), GranzB (scattered+), (**D**) ki-67 (hot spot LI about 20%+), CD56 (-), CD30 (-), ALK(ALK1), CD138 (-), EBER-CISH (-). Combined with clinical data, it was considered that non-Hodgkin's cytotoxic T-cell lymphoma involves bone marrow. (**A-D**, ×20).

**Fig. 4.** After two cycles of chemotherapy, a repeat PET/CT showed that all previous hypermetabolic lesions disappeared. **Panel A-C** showed PET, CT, and PET/CT fusion images of both kidneys, respectively. **Panel D-F** showed PET, CT and PET/CT fusion images of the left femoral neck, respectively. **(G)** displayed MIP image of the whole body.

CT. Subsequently, non-Hodgkin's cytotoxic T-cell lymphoma was confirmed by immunohistochemistry (Fig. 3) through left femoral neck puncture biopsy under the guidance of PET/CT and the patient was transferred from the infectious diseases to the haematology department for treatment. After two cycles of chemotherapy, a repeat PET/CT revealed that the metabolic activity returned to the normal level with a SUV<sub>max</sub> of 3.0 (Fig. 4).

Lymphoma can involve a variety of tissues and organs outside the lymph nodes. When there is no obvious morphological abnormality, traditional imaging may not pick up abnormal lesions. However, an <sup>18</sup>F-FDG PET/CT can be invaluable in diagnosing an occult malignancy and for subsequent evaluation for the remission of disease.

**Acknowledgment:** The authors would like to thank pathology expert Yu-fei Liu, haematology expert Jing-ming Guo and oncology expert Xin-hua Xu, The First Clinical Medical College of Three Gorges University, Yichang, China, for providing professional advice.

## Conflicts of Interest: None.

## Peng Wang<sup>1,2</sup> & Bang-Ping Cui<sup>1,2,\*</sup>

Received April 28, 2019

<sup>1</sup>Department of Infectious Diseases, The First Clinical Medical College of Three Gorges University & <sup>2</sup>Department of Nuclear Medicine, Yichang Central People's Hospital, Yichang, Hubei, P.R. China \*For correspondence: yccbp@126.com